Peptides, Inhibitors, Agonists
www.glpbio.com
Product Data Sheet
Product Name:Cat. No.:
Kynurenic acid sodium saltGC12566
Chemical Properties
Cas No.ChemicalNameCanonicalSMILESFormulaSolubilityGeneral tipsShippingCondition
2439-02-3
sodium 4-oxo-1,4-dihydroquinoline-2-carboxylateO=C(C1=CC=CC=C1N2)C=C2C([O-])=O.[Na+]C10H6NNaO3
Soluble in DMSO
M.WtStorage
211.15Desiccate at RT
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bathfor a while.Stock solution can be stored below -20℃ for several months.
Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice uponrequest.
Structure
Background
Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA,glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
Caution: Producthasnot been fully validated for medical applications. For research use only.
Tel: (626) 353-8530 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA
1www.glpbio.com
Peptides, Inhibitors, Agonists
www.glpbio.com
Product Data Sheet
GPR35 functions as a receptor for the kynurenine pathway intermediate kynurenic acid. Kynurenic acid elicitscalcium mobilization and inositol phosphate production in a GPR35-dependent manner in the presence of G qi/o
chimeric G proteins. Kynurenic acid stimulates [35S]guanosine 5′-O-(3-thiotriphosphate) binding in GPR35-expressingcells, an effect abolished by pertussis toxin treatment. Kynurenic acid also induces the internalization of GPR35[1].KYNA’s neuroinhibitory qualities and its neuroprotective and anticonvulsant effects are discovered using
concentrations of the compound in the millimolar range. This, as well as the low affinity of KYNA at each of the threeionotropic glutamate receptors responsible for these effects [NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate], together with the realization that KYNA concentrations in the mammalian brainare in the sub-micromolar range, suggested that other receptors might serve as targets of endogenous Kynurenicacid. Kynurenic acid, with a shallower inhibition curve and non-competitively, antagonizes α7nAChRs on culturedhippocampal neurons with an IC50 in the low micromolar range[2]
Kynurenic acid affects the activity of leukocytes in the peripheral blood of mice, although the lowest one (2.5 mg/L)has the most profound influence in contrast to the highest one (250 mg/L), which produces the weakest effect. Thelowest Kynurenic acid dose stimulates the proliferative response of T lymphocytes (p<0.05), after 7 and 28 days ofadministering the acid to the animals[3].Reference:
[1]. Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug4;281(31):22021-8.
[2]. Albuquerque EX, et al. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: factsand challenges. Biochem Pharmacol. 2013 Apr 15;85(8):1027-32.
[3]. Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral bloodleukocytes in mice. Cent Eur J Immunol. 2014;39(1):6-13.
Caution: Producthasnot been fully validated for medical applications. For research use only.
Tel: (626) 353-8530 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA
2www.glpbio.com
